Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Status: Enrolling
Updated:  6/14/2012
Mochida Investigative Site
961
mi
from 91732
Seattle, WA
Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Status: Enrolling
Updated: 6/14/2012
Mochida Investigative Site
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Japanese Bridging Study Conducted in the United States
A Randomized, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-791325 in Healthy Japanese Subjects
Status: Enrolling
Updated:  6/18/2012
Local Institution
21
mi
from 91732
Inglewood, CA
Japanese Bridging Study Conducted in the United States
A Randomized, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-791325 in Healthy Japanese Subjects
Status: Enrolling
Updated: 6/18/2012
Local Institution
21
mi
from 91732
Inglewood, CA
Click here to add this to my saved trials
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Status: Enrolling
Updated:  7/18/2012
Hartford Dispensary
2497
mi
from 91732
Hartford, CT
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Status: Enrolling
Updated: 7/18/2012
Hartford Dispensary
2497
mi
from 91732
Hartford, CT
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
316
mi
from 91732
Santa Clara, CA
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
316
mi
from 91732
Santa Clara, CA
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
1924
mi
from 91732
Decatur, GA
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
1924
mi
from 91732
Decatur, GA
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
1720
mi
from 91732
Park Ridge, IL
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
1720
mi
from 91732
Park Ridge, IL
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
1524
mi
from 91732
Rochester, MN
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
2423
mi
from 91732
Newark, NJ
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
2423
mi
from 91732
Newark, NJ
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
2435
mi
from 91732
New York, NY
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028 AM5)
A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials
Status: Enrolling
Updated:  8/15/2012
Clinical Research Facility
1189
mi
from 91732
San Antonio, TX
A Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028 AM5)
A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials
Status: Enrolling
Updated: 8/15/2012
Clinical Research Facility
1189
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
UCLA Medical Center-The Pfleger Liver Institute
13
mi
from 91732
Los Angeles, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
UCLA Medical Center-The Pfleger Liver Institute
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
UC San Diego
99
mi
from 91732
San Diego, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
UC San Diego
99
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of California, San Francisco
353
mi
from 91732
San Francisco, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of California, San Francisco
353
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of Colorado Hospital
825
mi
from 91732
Aurora, CO
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of Colorado Hospital
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of Miami
2320
mi
from 91732
Miami, FL
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of Miami
2320
mi
from 91732
Miami, FL
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Mount Sinai Medical Center
2324
mi
from 91732
Miami Beach, FL
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Mount Sinai Medical Center
2324
mi
from 91732
Miami Beach, FL
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Lahey Clinic Medical Center
2570
mi
from 91732
Burlington, MA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Lahey Clinic Medical Center
2570
mi
from 91732
Burlington, MA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Henry Ford Hospital
1965
mi
from 91732
Detroit, MI
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Henry Ford Hospital
1965
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
St. Louis University Hospital
1569
mi
from 91732
St. Louis, MO
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
St. Louis University Hospital
1569
mi
from 91732
St. Louis, MO
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Columbia University
2435
mi
from 91732
New York, NY
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Columbia University
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Thomas Jefferson University Hospital
2375
mi
from 91732
Philadelphia, PA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Thomas Jefferson University Hospital
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Baylor Health Care System
1225
mi
from 91732
Dallas, TX
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Baylor Health Care System
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
An Investigator-initiated Pilot Study Using Statins to Improve the Anti-HCV Response to Peginterferon Alfa 2-b and Ribavirin in Previous Non-responders
Status: Enrolling
Updated:  8/20/2012
Veterans Administration Medical Center (VAMC)
1164
mi
from 91732
Oklahoma City, OK
HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
An Investigator-initiated Pilot Study Using Statins to Improve the Anti-HCV Response to Peginterferon Alfa 2-b and Ribavirin in Previous Non-responders
Status: Enrolling
Updated: 8/20/2012
Veterans Administration Medical Center (VAMC)
1164
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1757
mi
from 91732
Mobile, AL
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1757
mi
from 91732
Mobile, AL
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
20
mi
from 91732
Los Angeles, CA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
20
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
101
mi
from 91732
San Diego, CA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
101
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
369
mi
from 91732
San Rafael, CA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
369
mi
from 91732
San Rafael, CA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
2062
mi
from 91732
Brandenton, FL
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
2062
mi
from 91732
Brandenton, FL
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
2321
mi
from 91732
Miami, FL
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
2321
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1709
mi
from 91732
Downers Grove, IL
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1709
mi
from 91732
Downers Grove, IL
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1793
mi
from 91732
Indianapolis, IN
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1655
mi
from 91732
New Orleans, LA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1655
mi
from 91732
New Orleans, LA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1401
mi
from 91732
Shreveport, LA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1401
mi
from 91732
Shreveport, LA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
2302
mi
from 91732
Baltimore, MD
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
2301
mi
from 91732
Baltimore, MD
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
2570
mi
from 91732
Burlington, MA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
2570
mi
from 91732
Burlington, MA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1965
mi
from 91732
Detroit, MI
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1965
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1509
mi
from 91732
Minneapolis, MN
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1509
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1501
mi
from 91732
Plymouth, MN
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1501
mi
from 91732
Plymouth, MN
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1343
mi
from 91732
Kansas City, MO
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1343
mi
from 91732
Kansas City, MO
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
1400
mi
from 91732
Springfield, MO
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
1400
mi
from 91732
Springfield, MO
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
2449
mi
from 91732
Manhasset, NY
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
2449
mi
from 91732
Manhasset, NY
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
2434
mi
from 91732
New York, NY
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials